Study #2023-0448
Pre-transplant purging and post-transplant MRD-guided maintenance therapy with Elranatamab in patients with high-risk multiple myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF
Description
To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Study phase:
Phase II
Physician name:
Qaiser Bashir
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-844-494-1356
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.